🇺🇸 BioNTech SEBNTX
Get BioNTech SE filings on Telegram the moment they are published.
Follow BioNTech SE on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 6-K — Foreign issuer report
Overview: Announced topline results from the DYNASTY-Breast02 Phase 3 trial showing trastuzumab pamirtecan met its primary endpoint for progression-free survival in HR+/HER2-low metastatic breast cancer.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest